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In recent issues of Critical Care, we read with concern 
the article by Pontes-Arruda and colleagues [1] and the 
ﬁ rst author’s reply to the letter from Machado (the latter 
two of which appear in [2]). Th e article and subsequent 
letters address eicosapentaenoic acid/gamma-linolenic 
acid (EPA/GLA) use in sepsis patients in the INTERSEPT 
(Investigating Nutritional Th erapy with EPA, GLA and 
Antioxidants Role in Sepsis Treatment) study.
We served as the principal investigators of this trial and 
come from sites that did not successfully include any 
patients or that included only a small number of patients. 
From this vantage point, we believe that Pontes-Arruda’s 
reply to Machado’s comments [2] did not clarify several 
important points.
As stated in the article [1], only ﬁ ve of the 12 sites 
successfully enrolled patients. However, the ﬁ rst author’s 
site was responsible for the inclusion of about 100 of the 
106 patients. We believe that this imbalance is relevant 
and that readers of Critical Care need to be aware of it. 
We disagree with Pontes-Arruda’s response [2] that all 
relevant limitations were already mentioned in the 
Discussion [1]. We found it diﬃ  cult to understand his 
aﬃ  rmation that the results were unaﬀ ected by the 
unbalanced distribution pattern of the patients, as any 
statistical analysis of the few patients from the other four 
sites would obviously be under powered. We also think he 
should clearly state the strategies that were used at his 
site to successfully enroll patients given that the 11 other 
sites, most of which are very skilled at performing 
intervention studies, failed to enroll similar numbers of 
patients.
Th e author’s explanation [2] of the Sequential Organ 
Failure Assessment (SOFA) ﬁ ndings is also not clear. We 
agree that it is perfectly possible for some patients to have 
a high SOFA score that may be insuﬃ  cient to fulﬁ ll the 
inclusion criteria. However, the median and inter quartile 
values shown in Table  3 [1] indicate that 75% of all 
patients had a SOFA score of more than 4. Th is would be 
a very unusual ﬁ nding in sepsis patients without 
signiﬁ cant organ dysfunction. Moreover, the interquartile 
interval in Table  3 indicates that at least 75% of the 
patients had platelet levels of more than 144  ×  109 cells 
per liter, a bilirubin level of less than 1.5  mg/dL, and a 
creatinine level of less than 1.6 mg/dL; as stated in the text 
[1], no patients had an arterial partial pressure of oxygen/
fraction of inspired oxygen (PaO2/FiO2) ratio of less than 
300. Th e high median and inter quartile values for the 
SOFA scores would be possible only in the presence of 
severe neurological or hemo dynamic dys func tion in the 
majority of the patients; this point, there fore, requires 
further explanation. Moreover, at least 50% of the patients 
had lactate levels of higher than 3.7  mmol/L, and this 
suggests that many patients already had signs of 
hypoperfusion (that is, severe sepsis) at inclusion. We 
believe that this paper needs more clarity as all of the 
above aspects are relevant for readers of Critical Care.
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L E T T E R
Author’s response
Alessandro Pontes-Arruda
Like any prospective randomized controlled trial, the 
INTERSEPT study has several limitations. As clearly 
mentioned in the paper [1], only ﬁ ve centers included 
patients. Th e primary center contributed 86% of them 
and such information was always available to all investi-
gators on the trial website. Th e primary reason why some 
institutions included patients while some did not is 
simple and was shared with all other investigators during 
the trial: the adoption of a more proactive approach. 
Centers that manage to include patients searched for 
them in the emergency and general wards. If a patient 
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was found and if a bed was available, they were trans-
ferred to be treated in the intensive care unit. Th is 
demands an extraordinary amount of time and eﬀ ort, and 
many centers decided not to follow this strategy. But 
there are other reasons for the lack of inclusion in other 
centers: It was impossible to blind the diet in two of the 
institutions, because their nutrition was prepared by 
independent companies located outside the hospital. 
More importantly, some institutions were clearly not 
interested in participating in the trial; we have recorded 
that ﬁ ve centers did not use their secret log-in/password 
a single time, not even to receive the electronic Clinical 
Research Forum mandatory online training. We want to 
highlight that all necessary care was taken to ensure the 
highest standards of quality and strict protocol adherence 
for the included patients. After its conclusion, the study 
was submitted to an extensive audit, and all study 
records, databases, institutional review board approvals, 
diet controls, written informed consents, and original 
medical records of the primary center were checked by 
independent auditors without any interference of the 
investigators, and only after this quality-control audit was 
the study submitted for publication. In the text of 
Machado, there is an assumption that the ‘the high 
median and interquartile values for the SOFA score 
would be possible only in the presence of severe neuro-
logical and hemodynamic dysfunction in the majority of 
the patients’ and this assumption is incorrect. All 
patients, indeed, did have a PaO2/FiO2 ratio of above 300, 
but many had a PaO2/FiO2 ratio of between 400 and 300, 
representing 1 SOFA point. Similarly, a bilirubin level of 
1.3 to 1.4 mg/dL and a platelet count of 144 to 149 × 109 
cells per liter do represent 1 SOFA point. In regard to 
lactate levels of included patients, please see Table 2 [1] 
and observe that the levels are still below the limit 
considered for metabolic failure. Finally, many included 
patients were older patients suﬀ ering from stroke and 
concomitant pneumonia, and this obviously means that 
they have some SOFA points in their neurologic 
evaluation. Th is study, like many others, does have 
several limitations, including the fact that care should be 
taken to extrapolate the ﬁ ndings to the overall population 
of patients with early sepsis. However, we believe that the 
true value of the INTERSEPT study is to serve as guide 
for future trials, including trials of a larger population of 
patients to validate the results of the present study.
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